Alnylam Pharmaceuticals
ALNY
#584
Rank
โ‚น3.943 T
Marketcap
โ‚น29,738
Share price
-1.68%
Change (1 day)
37.80%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): โ‚น15.44

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น8.18. In 2023 the company made an earnings per share (EPS) of -โ‚น320.78 an increase over its 2022 EPS that were of -โ‚น844.21.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น15.44
2023-โ‚น320.78-62%
2022-โ‚น844.2129.03%
2021-โ‚น654.29-3.36%
2020-โ‚น677.00-8.48%
2019-โ‚น739.717.67%
2018-โ‚น687.0039.74%
2017-โ‚น491.6212.94%
2016-โ‚น435.2838.84%
2015-โ‚น313.51-32.88%
2014-โ‚น467.09259.44%
2013-โ‚น129.95-31.25%
2012-โ‚น189.02

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
โ‚น668.83 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น187.67 2,194.62%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น3,918 47,811.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น248.99-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น66.34-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น21.81-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น112.68 1,277.78%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-โ‚น113.59-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA